Business Context and Reporting Period
Shuttle Pharmaceuticals Holdings, Inc. filed an unaudited Form 10-Q for the quarter and six months ended June 30, 2026. The company is a smaller reporting and emerging growth company whose common stock trades on Nasdaq under SHPH. Its activities now include the Molecule.ai pharmaceutical AI platform and the planned digital infrastructure and Dogecoin-mining operations of United Dogecoin, Inc. The company is winding down its Ropidoxuridine clinical trials.
On May 6, 2026, the company completed its merger with United Dogecoin. Because stockholder approval had not been obtained by June 30, 2026, the company did not obtain accounting control and did not consolidate United Dogecoin. Instead, it recorded an equity investment in United Dogecoin.
Key Financial Metrics
| Metric | Three months ended June 30 | Six months ended June 30 |
|---|---|---|
| Revenue | $0 in 2026 and 2025 | $0 in 2026 and 2025 |
| Operating expenses | $3.95 million in 2026; $3.91 million in 2025 | $6.17 million in 2026; $6.86 million in 2025 |
| Net loss | $3.15 million in 2026; $3.71 million in 2025 | $5.30 million in 2026; $6.76 million in 2025 |
| Net loss per share | $3.10 in 2026; $32.91 in 2025 | $6.97 in 2026; $88.24 in 2025 |
| Cash used in operating activities | Not separately provided | $2.98 million in 2026; $5.88 million in 2025 |
| Cash provided by financing activities | Not separately provided | $8.21 million in 2026; $8.78 million in 2025 |
| Cash and cash equivalents | $90,238 at June 30, 2026, versus $334,005 at December 31, 2025 |
At June 30, 2026, total assets were $22.81 million, including a $13.68 million investment in United Dogecoin and $8.65 million of net Molecule.ai developed-technology assets. Total liabilities were $3.63 million and stockholders’ equity was $19.18 million. Current assets were $396,353 and current liabilities were $3.48 million, resulting in a working capital deficit of approximately $3.08 million.
The company had no conventional debt principal outstanding identified in the balance sheet at June 30, 2026. It had a $35,751 derivative liability, $250,000 of contingent consideration payable, $361,135 due to United Dogecoin, and operating lease liabilities totaling $195,158. The filing does not provide a meaningful operating margin because revenue was zero.
Material Changes Versus Prior Comparable Period
- Revenue remained zero for both the quarter and six-month period.
- Six-month net loss improved by $1.46 million, or approximately 22%, primarily because operating expenses declined and the company recognized a $755,121 gain on extinguishment of Molecule.ai-related debt.
- Six-month operating expenses decreased 10% to $6.17 million. Research and development expense declined 88% to $322,901 following the Ropidoxuridine trial wind-down, lower headcount, retirement of the former chief scientific officer, and elimination of third-party CRO expenses.
- General and administrative expense increased 7% to $3.15 million, including $1.26 million of investor-relations and marketing costs and $1.26 million of amortization related to the Molecule.ai technology.
- Legal and professional expense increased 105% to $2.70 million, primarily due to the United Dogecoin merger, May 2026 PIPE financing, Molecule.ai amendment, valuation, accounting, and compliance work.
- Cash used in operations improved by $2.90 million from the prior-year period, but investing cash outflows of $5.47 million were incurred for Molecule.ai installment and milestone payments and capitalized software.
- Common shares outstanding increased to 1,001,165 at June 30, 2026 from 202,362 at December 31, 2025. The company also had 9,423 Series B-1 preferred shares and 1,910 Series B-2 preferred shares outstanding, with stated liquidation preferences of approximately $48.3 million and $9.6 million, respectively.
- The company completed a 1-for-10 reverse stock split on June 11, 2026, following a prior 1-for-25 reverse split in June 2025.
Financing, Outlook, Risks, and Unusual Items
- In March 2026, the company raised approximately $3.5 million gross, or approximately $3.2 million net, through common stock and pre-funded warrants.
- In May 2026, the PIPE financing generated approximately $9.6 million gross and $8.4 million net proceeds. It included 1,910 Series B-2 convertible preferred shares and warrants exercisable for up to 927,185 common shares at $10.30 per share. Additional pre-funded warrants were contingent on stockholder approval and specified milestones.
- Management stated that existing cash and recent equity proceeds are insufficient to fund operations for the next twelve months. The filing raises substantial doubt about the company’s ability to continue as a going concern.
- Management expects continued negative operating cash flow and is targeting a further capital raise of approximately $120 million to $150 million in connection with a potential data-center land transaction and expansion of United Dogecoin’s digital infrastructure. Completion of the financing and land transaction is not guaranteed.
- United Dogecoin had purchased 500 mining rigs and initiated a co-location arrangement, but the filing states that cryptocurrency mining operations had not yet commenced as of the filing date. United Dogecoin remains dependent on financing, power availability, data-center arrangements, equipment procurement, and Dogecoin market conditions.
- The Molecule.ai asset acquisition carried a remaining developed-technology balance of $8.65 million at June 30, 2026, amortized over an estimated four-year useful life. The company paid $3.65 million of installment obligations and $1.75 million of milestone consideration during the six months.
- A legal proceeding brought by One Eyed Jack Enterprises seeks approximately $250,000 and 2.99% of United Dogecoin or equivalent preferred stock. United Dogecoin has moved to dismiss the case, which remains in its early stages.
- Management reported ineffective disclosure controls and material weaknesses in accounting close procedures, review and segregation of duties, information-technology general controls, communication of material contracts, and technical accounting and valuation expertise. Remediation efforts are ongoing.
- Subsequent to quarter-end, stockholders approved the relevant merger, PIPE, warrant, equity-plan, and corporate-name proposals. By September 14, 2026, the company reported issuing 2,869,595 shares upon conversion of Series B-1 preferred stock, 867,887 shares upon conversion of Series B-2 preferred stock, approximately 927,185 common warrants, and 9,741,751 pre-funded warrants.
Most Important Facts for Investors to Verify
- Whether the company can raise the targeted $120 million to $150 million and obtain sufficient liquidity before existing cash is exhausted.
- The terms, dilution, conversion mechanics, and exercise status of the Series B-1 and Series B-2 preferred stock, common warrants, pre-funded warrants, and stock options.
- Whether United Dogecoin has commenced mining, finalized power and co-location agreements, and achieved the operating and rig milestones tied to additional warrant issuance.
- The valuation and recoverability of the $13.68 million United Dogecoin investment and $8.65 million Molecule.ai intangible asset.
- The effect of the September 2026 stockholder approvals and subsequent security issuances on the company’s fully diluted share count and control structure.
- Progress in remediating the disclosed material weaknesses in internal control over financial reporting.
- The outcome and potential dilution or liability from the One Eyed Jack Enterprises litigation and other Molecule.ai-related obligations.
- Exposure to Dogecoin price volatility, mining economics, power costs, regulatory changes, cybersecurity incidents, third-party custodians, and co-location providers.